Fertility and sterility · 2026
Epigenetic clock timing in the endometrium of women undergoing in vitro fertilization.
СтатьяНаблюдательное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Del Aguila Nataly, Sanz Francisco Jose, Sebastian-Leon Patricia, Romeu Mónica, Martinez-Martinez Asunta, Parraga-Leo Antonio, Monzó Ana, Del Carmen Vidal Maria, Sanchez-Ribas Immaculada, Ferrando Marcos, Esteve-Moreno Rebeca, Pellicer Antonio, Diaz-Gimeno Patricia
Аннотация
OBJECTIVE: To evaluate endometrial epigenetic age acceleration (EEAA)-the difference between epigenetic and chronological age-in endometrial tissue from patients undergoing in vitro fertilization (IVF), using Horvath's DNA-methylation-based clock.
DESIGN: Cross-sectional observational study with prospective, multicenter data collection.
SUBJECTS: A total of 91 Caucasian women aged 28.45-49.99 years undergoing IVF. All the participants followed a standardized hormone-replacement protocol (oral estradiol valerate and vaginal progesterone) and met the following inclusion criteria: body mass index 19-29.9 kg/m2, endometrial thickness >6.5 mm, and absence of systemic or interfering conditions.
EXPOSURE: Endometrial biopsies collected in the mid-secretory phase.
MAIN OUTCOME MEASURES: Endometrial epigenetic age acceleration in an IVF population measured using Horvath's epigenetic clock.
RESULTS: Endometrial epigenetic age in this population was 46.45 years, 5.79 years significantly higher than chronological age. EEAA significantly decreased with increasing age: 12.29 years in women aged ≤35 years, 10.31 years in those aged 36-40, 7.60 years in the group aged 41-45, and 3.40 years in women aged >45.
CONCLUSION: The endometrium of women undergoing IVF shows significant epigenetic age acceleration, which is most pronounced at younger maternal ages. Although further studies linking EEAA to clinical outcomes are needed, EEAA may serve as a biomarker of endometrial health and fertility potential.
DESIGN: Cross-sectional observational study with prospective, multicenter data collection.
SUBJECTS: A total of 91 Caucasian women aged 28.45-49.99 years undergoing IVF. All the participants followed a standardized hormone-replacement protocol (oral estradiol valerate and vaginal progesterone) and met the following inclusion criteria: body mass index 19-29.9 kg/m2, endometrial thickness >6.5 mm, and absence of systemic or interfering conditions.
EXPOSURE: Endometrial biopsies collected in the mid-secretory phase.
MAIN OUTCOME MEASURES: Endometrial epigenetic age acceleration in an IVF population measured using Horvath's epigenetic clock.
RESULTS: Endometrial epigenetic age in this population was 46.45 years, 5.79 years significantly higher than chronological age. EEAA significantly decreased with increasing age: 12.29 years in women aged ≤35 years, 10.31 years in those aged 36-40, 7.60 years in the group aged 41-45, and 3.40 years in women aged >45.
CONCLUSION: The endometrium of women undergoing IVF shows significant epigenetic age acceleration, which is most pronounced at younger maternal ages. Although further studies linking EEAA to clinical outcomes are needed, EEAA may serve as a biomarker of endometrial health and fertility potential.